Press Releases

Acceptance of SBP-101 Abstract for Poster Presentation at American Association for Cancer Research (AACR)

Panbela Therapeutics, Inc. to Acquire Cancer Prevention Pharmaceuticals, Inc.

• Creates late-stage, diversified pipeline that uses a multi-targeted approach to reset dysregulated biology to address considerable unmet needs
• Combined pipeline extends from pre-clinical to registration studies, with near-term clinical and regulatory milestones
• Acquired lead asset will begin a fully-funded registration trial anticipated to start by year-end

Panbela Initiates a Randomized, Double-Blind, Placebo-Controlled Study (ASPIRE) of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma

Panbela Presents Clinical Data on Phase 1b Clinical Trial of SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic PDA at 2022 ASCO GI Meeting

Interim data presented in poster reflects median overall survival of 12.0 months, not yet final, and an objective response rate of 48%, both greater than historical rates reported for standard of care

Panbela Announces Positive Preclinical Data Strongly Supporting the Activity of SBP-101 in Ovarian Cancer Cell Lines

Development Program for SBP-101’s Expansion into Ovarian Cancer Expected in 1H 2022

Panbela Announces Acceptance of Abstract for Poster Presentation at American Society of Clinical Oncology Gastrointestinal Cancers Symposium

Panbela Provides Business Update and Reports Q3 2021 Financial Results

Panbela Schedules Conference Call on Nov 10 to Report Q3 2021 Financial Results

Panbela to Present at Upcoming Investor Conferences

H.C. Wainwright 23rd Annual Global Investment Conference: September 13th to 15th, 2021

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit: September 20-23

Panbela Provides Business Update and Reports Q2 2021 Financial Results